Nextcure Inc (NXTC) Stock Price, Quote & News

Company Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease;...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 399 4900

Website: www.nextcure.com

Address:

9000 Virginia Manor Road, Suite 200, Beltsville, United States

INEEDMONEY87 Aug. 18 at 10:40 PM

$NXTC whelp gambling alone…

0 · Reply

INEEDMONEY87 Aug. 18 at 3:23 PM

$NXTC or makin handle?

0 · Reply

INEEDMONEY87 Aug. 18 at 2:13 PM

$NXTC so its done and gona sell to zero?

0 · Reply

INEEDMONEY87 Aug. 14 at 7:43 PM

$NXTC another 13g, this thing caught a lot of institutions off guard..

0 · Reply

INEEDMONEY87 Aug. 14 at 6:26 PM

$NXTC seems like basing up here....such sharp face ripping action here hard to tell...

0 · Reply

INEEDMONEY87 Aug. 14 at 5:38 PM

$NXTC if that bigger buyer on the bid is a spoof i will probably be out...

0 · Reply

INEEDMONEY87 Aug. 14 at 5:37 PM

$NXTC sure slow rolled that one.... with some more fkery, about to call it this girl getting ugly

0 · Reply

INEEDMONEY87 Aug. 14 at 5:35 PM

$NXTC o looks like he still hooked we good...

0 · Reply

INEEDMONEY87 Aug. 14 at 4:49 PM

$NXTC or jsut dollar spread snaky dragon?

0 · Reply

INEEDMONEY87 Aug. 14 at 2:19 PM

$NXTC squeeze over?

0 · Reply

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

2026-08-06T20:16:43.000Z - 12 days ago

NextCure reports Q2 EPS ($2.80), consensus ($1.92)

Aug 6, 2026, 4:00 PM EDT - 12 days ago

NextCure Quarterly report: Q2 2026

Aug 6, 2026, 4:00 PM EDT - 12 days ago

NextCure Earnings release: Q2 2026

2026-07-16T14:45:56.000Z - 4 weeks ago

NextCure trading resumes

2026-07-16T14:40:39.000Z - 4 weeks ago

NextCure trading halted, volatility trading pause

2026-07-14T12:26:44.000Z - 5 weeks ago

Why Is Penny Stock NextCure (NXTC) Up Today?

2026-07-14T10:05:31.000Z - 5 weeks ago

NextCure, Avere Therapeutics enter definitive merger agreement

2026-07-14T10:05:13.000Z - 5 weeks ago

NextCure, Avere Therapeutics enter definitive merger agreement

Jul 14, 2026, 6:00 AM EDT - 5 weeks ago

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

Jul 1, 2026, 8:00 AM EDT - 6 weeks ago

NextCure Slides: Corporate presentation

Jun 18, 2026, 11:00 AM EDT - 2 months ago

NextCure Transcript: AGM 2026

Jun 4, 2026, 8:00 AM EDT - 2 months ago

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

Jun 2, 2026, 8:00 AM EDT - 2 months ago

NextCure Transcript: KOL event

Jun 2, 2026, 8:00 AM EDT - 2 months ago

NextCure Press release: KOL event

Jun 2, 2026, 8:00 AM EDT - 2 months ago

NextCure Slides: KOL event

2026-06-02T10:10:04.000Z - 2 months ago

NextCure share weakness overdone, says Lucid Capital

2026-06-01T13:49:45.000Z - 2 months ago

NextCure presents Phase 1 data for SIM0505 in gynecologic cancers

Jun 1, 2026, 8:00 AM EDT - 2 months ago

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

2026-05-11T12:05:03.000Z - 3 months ago

NextCure initiated with a Buy at Lucid Capital

2026-05-07T22:46:09.000Z - 3 months ago

NextCure reports Q1 EPS ($1.87), consensus ($2.03)

May 7, 2026, 4:05 PM EDT - 3 months ago

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 7:00 AM EDT - 3 months ago

NextCure Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

NextCure Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

NextCure Slides: Corporate presentation

2026-05-04T12:10:48.000Z - 3 months ago

NextCure initiates dose optimization portion of SIM0505 study

May 4, 2026, 7:05 AM EDT - 3 months ago

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

Apr 24, 2026, 8:00 AM EDT - 4 months ago

NextCure Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

NextCure Proxy statement: Proxy filing

Apr 21, 2026, 10:15 AM EDT - 4 months ago

NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

2026-04-07T14:31:45.000Z - 4 months ago

NextCure granted Fast Track Designation for SIM0505 by FDA

Apr 7, 2026, 8:05 AM EDT - 4 months ago

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

Mar 31, 2026, 4:05 PM EDT - 5 months ago

NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

Mar 5, 2026, 4:05 PM EST - 5 months ago

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

Mar 5, 2026, 4:00 PM EST - 5 months ago

NextCure Annual report: Q4 2025

Mar 5, 2026, 4:00 PM EST - 5 months ago

NextCure Earnings release: Q4 2025

2026-03-02T14:55:36.000Z - 6 months ago

NextCure trading resumes

2026-03-02T14:45:08.000Z - 6 months ago

NextCure trading halted, volatility trading pause

2026-01-23T12:05:31.000Z - 7 months ago

NextCure expects SIM0505 Phase 1 dose escalation data update in Q2

Jan 23, 2026, 7:00 AM EST - 7 months ago

NextCure Provides Business Update

Jan 21, 2026, 7:00 AM EST - 7 months ago

NextCure Slides: Corporate presentation

Dec 3, 2025, 11:00 AM EST - 9 months ago

NextCure Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-11-26T21:05:41.000Z - 9 months ago

NextCure files to sell 2.52M shares of common stock for holders

Nov 26, 2025, 7:00 AM EST - 9 months ago

NextCure Registration statement: Registration Filing

Nov 20, 2025, 8:00 AM EST - 9 months ago

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

2025-11-17T13:16:03.000Z - 9 months ago

NextCure announces closing of $21.5M PIPE financing

Nov 17, 2025, 8:00 AM EST - 9 months ago

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

2025-11-12T13:25:47.000Z - 9 months ago

NextCure prices 2.5M shares at $8.52 in private placement

Nov 12, 2025, 8:00 AM EST - 9 months ago

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

Nov 5, 2025, 4:05 PM EST - 10 months ago

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:00 PM EST - 10 months ago

NextCure Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 10 months ago

NextCure Earnings release: Q3 2025

Oct 16, 2025, 8:05 AM EDT - 10 months ago

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

Sep 8, 2025, 4:00 PM EDT - 1 year ago

NextCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 1 year ago

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:00 PM EDT - 1 year ago

NextCure Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

NextCure Earnings release: Q2 2025

Jul 24, 2025, 4:05 PM EDT - 1 year ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Jul 18, 2025, 8:00 AM EDT - 1 year ago

NextCure Registration statement: Registration Filing

Jun 16, 2025, 10:03 AM EDT - 1 year ago

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

Jun 16, 2025, 7:05 AM EDT - 1 year ago

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

May 29, 2025, 4:05 PM EDT - 1 year ago

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

May 19, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

May 1, 2025, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 4:00 PM EDT - 1 year ago

NextCure Quarterly report: Q1 2025

May 1, 2025, 4:00 PM EDT - 1 year ago

NextCure Earnings release: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

Apr 10, 2025, 8:45 AM EDT - 1 year ago

NextCure Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 7:00 AM EDT - 1 year ago

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

Mar 6, 2025, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Mar 6, 2025, 4:00 PM EST - 1 year ago

NextCure Earnings release: Q4 2024

Mar 6, 2025, 4:00 PM EST - 1 year ago

NextCure Annual report: Q4 2024

Jan 10, 2025, 8:05 AM EST - 1 year ago

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

Dec 10, 2024, 8:05 AM EST - 1 year ago

NextCure Announces Acceptance of IND Application for LNCB74

Dec 5, 2024, 12:00 PM EST - 1 year ago

NextCure Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 19, 2024, 8:05 AM EST - 1 year ago

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Nov 7, 2024, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 3:00 PM EST - 1 year ago

NextCure Earnings release: Q3 2024

Nov 7, 2024, 3:00 PM EST - 1 year ago

NextCure Quarterly report: Q3 2024

Nov 5, 2024, 4:05 PM EST - 1 year ago

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 2 years ago

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Sep 16, 2024, 8:05 AM EDT - 2 years ago

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Aug 1, 2024, 4:00 PM EDT - 2 years ago

NextCure Quarterly report: Q2 2024

Aug 1, 2024, 4:00 PM EDT - 2 years ago

NextCure Earnings release: Q2 2024

Jun 27, 2024, 7:00 AM EDT - 2 years ago

NextCure Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 20, 2024, 4:10 PM EDT - 2 years ago

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 30, 2024, 4:05 PM EDT - 2 years ago

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

May 2, 2024, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 4:00 PM EDT - 2 years ago

NextCure Quarterly report: Q1 2024

May 2, 2024, 4:00 PM EDT - 2 years ago

NextCure Earnings release: Q1 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

NextCure Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

NextCure Proxy statement: Proxy Filing

Apr 24, 2024, 4:05 PM EDT - 2 years ago

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Apr 16, 2024, 8:00 AM EDT - 2 years ago

NextCure Proxy statement: Proxy Filing

Apr 11, 2024, 12:45 PM EDT - 2 years ago

NextCure Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 8, 2024, 7:00 AM EDT - 2 years ago

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Apr 4, 2024, 7:05 AM EDT - 2 years ago

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Apr 2, 2024, 7:00 AM EDT - 2 years ago

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 21, 2024, 8:55 AM EDT - 2 years ago

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 8:00 AM EDT - 2 years ago

NextCure Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

NextCure Annual report: Q4 2023

Mar 5, 2024, 8:05 AM EST - 2 years ago

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Jan 18, 2024, 4:05 PM EST - 2 years ago

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Dec 21, 2023, 7:05 AM EST - 2 years ago

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Dec 14, 2023, 6:45 AM EST - 2 years ago

NextCure Provides Year-End Clinical Pipeline Updates

Nov 30, 2023, 1:30 PM EST - 2 years ago

NextCure Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 20, 2023, 7:00 AM EST - 2 years ago

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 15, 2023, 4:05 PM EST - 2 years ago

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

Nov 2, 2023, 5:00 PM EDT - 3 years ago

NextCure Quarterly report: Q3 2023

Nov 2, 2023, 5:00 PM EDT - 3 years ago

NextCure Earnings release: Q3 2023

Nov 2, 2023, 4:05 PM EDT - 3 years ago

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

INEEDMONEY87 Aug. 18 at 10:40 PM

$NXTC whelp gambling alone…

0 · Reply

INEEDMONEY87 Aug. 18 at 3:23 PM

$NXTC or makin handle?

0 · Reply

INEEDMONEY87 Aug. 18 at 2:13 PM

$NXTC so its done and gona sell to zero?

0 · Reply

INEEDMONEY87 Aug. 14 at 7:43 PM

$NXTC another 13g, this thing caught a lot of institutions off guard..

0 · Reply

INEEDMONEY87 Aug. 14 at 6:26 PM

$NXTC seems like basing up here....such sharp face ripping action here hard to tell...

0 · Reply

INEEDMONEY87 Aug. 14 at 5:38 PM

$NXTC if that bigger buyer on the bid is a spoof i will probably be out...

0 · Reply

INEEDMONEY87 Aug. 14 at 5:37 PM

$NXTC sure slow rolled that one.... with some more fkery, about to call it this girl getting ugly

0 · Reply

INEEDMONEY87 Aug. 14 at 5:35 PM

$NXTC o looks like he still hooked we good...

0 · Reply

INEEDMONEY87 Aug. 14 at 4:49 PM

$NXTC or jsut dollar spread snaky dragon?

0 · Reply

INEEDMONEY87 Aug. 14 at 2:19 PM

$NXTC squeeze over?

0 · Reply

Zephix Aug. 13 at 8:39 PM

$NXTC night34

0 · Reply

INEEDMONEY87 Aug. 13 at 8:08 PM

$NXTC is that another 13g?

0 · Reply

IamJdubs Aug. 13 at 5:47 PM

$NXTC this thing wants to rip our faces off

0 · Reply

INEEDMONEY87 Aug. 13 at 4:19 PM

$NXTC if your short here and not covering your insane

0 · Reply

IamJdubs Aug. 13 at 12:56 PM

$NXTC bullish as f

0 · Reply

elmono Aug. 13 at 9:55 AM

$NXTC easiest short in the world. Real value is way below 2

0 · Reply

Runningman79 Aug. 12 at 8:32 PM

$NXTC Love how quiet this page is. Silence very often speaks volumes We have an absolute beast here A true squeeze play I’m locked and loaded with 20k shares with a 5.31 average About to make a whole lot of money here Until that boom.. my mood

0 · Reply

Runningman79 Aug. 12 at 7:51 PM

$DFNS $NXTC Trust It’s about to go

0 · Reply

takethemonayy Aug. 12 at 7:51 PM

$NXTC

0 · Reply

Runningman79 Aug. 12 at 6:41 PM

$NXTC Soon 🌙 Soon

0 · Reply

IamJdubs Aug. 12 at 6:19 PM

$NXTC this thing wants to rip our faces off

0 · Reply

IamJdubs Aug. 12 at 6:18 PM

$NXTC bullish as f

0 · Reply

Market Cap	27.85M
Revenue (ttm)	0.00
Net Income (ttm)	-55.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	257,300
Avg Vol	2,689,356
Day's Range	N/A - N/A
Shares Out	3.61M
Stochastic %K	45%
Beta	1.26
Analysts	Sell
Price Target	$20.00